7837 related articles for article (PubMed ID: 2181070)
21. Physiology of natural killer cells. In vivo regulation of progenitors by interleukin 3.
Kalland T
J Immunol; 1987 Dec; 139(11):3671-5. PubMed ID: 3500227
[TBL] [Abstract][Full Text] [Related]
22. Induction of bone marrow allograft rejection and hybrid resistance in nonresponder recipients by antibody: is there evidence for a dual receptor interaction in acute marrow graft rejection?
Dennert G; Anderson CG; Warner J
J Immunol; 1986 Jun; 136(11):3981-6. PubMed ID: 3517162
[TBL] [Abstract][Full Text] [Related]
23. Interleukin-2 and syngeneic bone marrow transplantation in a murine fibrosarcoma model.
Ho SP; Stebler B; Ershler WB
Lymphokine Cytokine Res; 1991 Apr; 10(1-2):101-4. PubMed ID: 1873353
[TBL] [Abstract][Full Text] [Related]
24. Effect of various cytokines and growth factors on the interleukin-2-dependent in vitro differentiation of natural killer cells from bone marrow.
Migliorati G; Cannarile L; Herberman RB; Riccardi C
Nat Immun Cell Growth Regul; 1989; 8(1):48-55. PubMed ID: 2654622
[TBL] [Abstract][Full Text] [Related]
25. H-2 antigen expression and sensitivity of BL6 melanoma cells to natural killer cell cytotoxicity.
Gorelik E; Gunji Y; Herberman RB
J Immunol; 1988 Mar; 140(6):2096-102. PubMed ID: 3126240
[TBL] [Abstract][Full Text] [Related]
26. Augmentation of the antimetastatic effect of anticoagulant drugs by immunostimulation in mice.
Gorelik E
Cancer Res; 1987 Feb; 47(3):809-15. PubMed ID: 3802083
[TBL] [Abstract][Full Text] [Related]
27. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
Björkdahl O; Dohlsten M; Sjögren HO
Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
[TBL] [Abstract][Full Text] [Related]
28. Cytokine-induced resistance to microbial infections in normal, immunosuppressed and bone marrow transplanted mice.
Leshem B; Dekel R; Bercovier H; Tchakirov R; Polacheck I; Zakay-Rones Z; Schlesinger M; Kedar E
Bone Marrow Transplant; 1992 Jun; 9(6):471-7. PubMed ID: 1628132
[TBL] [Abstract][Full Text] [Related]
29. Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2.
Hornung RL; Back TC; Zaharko DS; Urba WJ; Longo DL; Wiltrout RH
J Immunol; 1988 Nov; 141(10):3671-9. PubMed ID: 2460546
[TBL] [Abstract][Full Text] [Related]
30. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
Mulé JJ; Krosnick JA; Rosenberg SA
J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
[TBL] [Abstract][Full Text] [Related]
31. Comparison of natural killer activity of human bone marrow and blood cells in cultures containing IL-2, IL-7 and IL-12.
Wong EK; Eaves C; Klingemann HG
Bone Marrow Transplant; 1996 Jul; 18(1):63-71. PubMed ID: 8831997
[TBL] [Abstract][Full Text] [Related]
32. Cytokines involved in the augmentation of murine natural killer cell activity by pyrimidinones in vivo.
Richard KA; Mortensen RF; Tracey DE
J Biol Response Mod; 1987 Dec; 6(6):647-63. PubMed ID: 2453616
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.
Oniki S; Nagai H; Horikawa T; Furukawa J; Belladonna ML; Yoshimoto T; Hara I; Nishigori C
Cancer Res; 2006 Jun; 66(12):6395-404. PubMed ID: 16778218
[TBL] [Abstract][Full Text] [Related]
34. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.
Osaki T; Péron JM; Cai Q; Okamura H; Robbins PD; Kurimoto M; Lotze MT; Tahara H
J Immunol; 1998 Feb; 160(4):1742-9. PubMed ID: 9469432
[TBL] [Abstract][Full Text] [Related]
35. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
[TBL] [Abstract][Full Text] [Related]
36. Role of interleukin 2 (IL 2) and hemopoietin-1 (H-1) in the generation of mouse natural killer (NK) cells from primitive bone marrow precursors.
Migliorati G; Cannarile L; Herberman RB; Bartocci A; Stanley ER; Riccardi C
J Immunol; 1987 Jun; 138(11):3618-25. PubMed ID: 2884255
[TBL] [Abstract][Full Text] [Related]
37. Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma.
Wang Q; Yu H; Ju DW; He L; Pan JP; Xia DJ; Zhang LH; Cao X
Gene Ther; 2001 Apr; 8(7):542-50. PubMed ID: 11319621
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-18 gene transfer increases antitumor effects of suicide gene therapy through efficient induction of antitumor immunity.
Ju DW; Yang Y; Tao Q; Song WG; He L; Chen G; Gu S; Ting CC; Cao X
Gene Ther; 2000 Oct; 7(19):1672-9. PubMed ID: 11083476
[TBL] [Abstract][Full Text] [Related]
39. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
40. Antileukemic effect of interleukin-2-transduced murine bone marrow after autologous transplantation.
Tam YK; Klingemann HG
Biol Blood Marrow Transplant; 1999; 5(3):144-54. PubMed ID: 10392960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]